SCHEMBL13588591

SCHEMBL13588591

CC(=O)Nc1ccc(-c2ccnc(Nc3cccc(NC(=O)c4c(Cl)cccc4I)c3)n2)c(Cl)c1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 10/20 0.72
AURKA O14965 1/20 0.54
AURKB Q96GD4 1/20 0.54
PLK1 P53350 1/20 0.53
TYK2 P29597 2/20 0.51
JAK1 P23458 1/20 0.51
PIK3CA P42336 2/20 0.50
PIK3CB P42338 2/20 0.50
PIK3CG P48736 2/20 0.50
JAK3 P52333 1/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
ABL1 P00519 5/20 0.47
BCR P11274 4/20 0.46
SRC P12931 3/20 0.46
PDGFRB P09619 2/20 0.46
PDGFRA P16234 2/20 0.46
PRKCA P17252 2/20 0.46
PRKCD Q05655 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4378411 0.93 JAK2 (0.82) JAK2AURKAAURKBPLK1TYK2
SCHEMBL4375081 0.84 JAK2 (1.00) JAK2AURKAAURKBPLK1TYK2
SCHEMBL4378544 0.83 JAK2 (0.67) JAK2TYK2JAK1PIK3CAPIK3CB
SCHEMBL4375131 0.80 JAK2 (0.72) JAK2PLK1JAK3HDAC1HDAC6
SCHEMBL13588582 0.80 JAK2 (0.69) JAK2AURKATYK2JAK1PIK3CG
SCHEMBL4583044 0.80 JAK2 (0.61) JAK2AURKAAURKBPLK1PIK3CA
SCHEMBL13588604 0.78 JAK2 (0.80) JAK2PLK1JAK3HDAC1HDAC6
SCHEMBL13588620 0.78 JAK2 (0.61) JAK2AURKAAURKBTYK2JAK1
SCHEMBL4378751 0.78 JAK2 (0.88) JAK2AURKAPLK1JAK3HDAC1
SCHEMBL4379888 0.77 JAK2 (1.00) JAK2AURKAAURKBPLK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298830-A1 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298830-A1 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use JAK2, JAK1, JAK3 JAK2 1/4885AURKA 895/4885AURKB 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.